Error loading player: No playable sources found
AM24-MN-12-O
AM24-MN-12-O: Preventing Blood Product Tracking In a Mass Casualty Event from Becoming a Disaster (Enduring)
Date
October 23, 2024
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$30
Standard Price
Members save $5
This product is also available as part of the following products:
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…
Many hospitals have administrative and clinical elements for Mass Casualty Events (MCE) but often do not include how to determine the number of blood products that will be needed and rarely how the products will be distributed or tracked. Due to the multiple regulatory concerns in the Transfusion Service, ensuring final disposition for each blood product in a chaotic situation is a major concern. These regulatory concerns have to be balanced with the need to get blood products to the patient quickly and efficiently. This program will look into how to determine how many blood products might be needed in an MCE. We will also share an example of a process to quickly prepare blood products with paper tracking and downtime administration for distribution during MCE.
Learning Objectives
- Discuss what type of products are immediately available for Mass Casualty Event (MCE) and how these can be used to start the MCE process.
- Discuss information regarding how many blood products are routinely used during a MCE and how to calculate an estimate of blood products that might be needed.
- Share an example of a paper tracking form that might be used for MCE to quickly release blood products to a patient.
- Determine how to implement a blood product distribution program for MCE at a hospital site that meets the urgent demand as well as the regulatory tracking requirements.
Speakers
Moderator
Related Products
AM24-MN-02-O: A Multidisciplinary Approach to Delivering Comprehensive Care for Chronically Transfused Children and Adults with Sickle Cell Disease: An Overview of the Vanderbilt Sickle Cell Pathways Experience (Enduring)
Sickle cell disease is an inherited red blood disorder characterized by a beta globin gene mutation that can result in potentially life-threatening vaso-occlusive complications…
AM24-MN-22-O: What is the Status of the U.S. Blood Supply? Preliminary Findings of the 2023 NBCUS and Latest Trends From Blood Collectors (Enduring)
The biennially conducted National Blood Collection and Utilization Survey (NBCUS) provides the most comprehensive estimation of blood collection and utilization in the United States…
AM24-MN-10-O: Should Rh Immune Globulin Be Administered After First Trimester Bleeding Events? (Enduring)
AABB Standards 5.30.2, 5.30.3, and 5.30.4 require that Rh negative women who are pregnant or who have been pregnant recently be considered for Rh Immune Globulin administration when the Rh type of the fetus/neonate is unknown or positive when tested for D or weak D…
AM24-SN-11-O: Why is My Blood Product Being Quarantined? Investigations that Happen Behind the Scenes (Enduring)
There are various reasons requiring blood products to be isolated from the general inventory, with recipient safety being the top priority…
